Home | Careers | BI | Contact us

Newsroom

Apricus Biosciences and Neopharm Group Sign Licensing Agreement...

December 26, 2011

Feb, 2011 Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group (“Neopharm”) the exclusive rights to market and sell VitarosĀ®, Apricus Bio’s treatment for erectile…

Neopharm Group Will Commercialize NPS’s Teduglutide in...

December 21, 2011

Neopharm Group announced that they have entered into a definitive agreement with NPS Pharmaceuticals, Inc. which licenses to Neopharm the rights to develop and commercialize teduglutide in Israel, for the treatment of gastrointestinal disorders. The…

← Previous Page

Home | About Us | Companies | Partnering | Research | Corporate Citizenship | Careers | Newsroom | Contact | Legal Notice

All Rights reserved, Neopharm Group, Israel | Design by: VAZA | Developed by: The Shark Lady